ESC Congress 2017

26 - 30 August 2017, Barcelona - Spain

Session Details

Poster session 4: Stroke prevention
Mon 28 Aug 08:30 - 12:30 Miscellaneous Poster Session Posters - Poster Area
Learning Objectives: Posters are on display from 08:30 – 12:30. Presenters will be by their poster during the coffee break from 10:00 and 11:00 for posters viewing time.

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Related documents
08:30P3579Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT studyAgata TYMINSKA (Warsaw, Poland)
08:30P3580Which factors influence the choice of a non-vitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINT-AF registry.Milan GUPTA (Brampton, Canada)
08:30P3581Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload studyHendrik BONNEMEIER (Kiel, Germany)
08:30P3582Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differencesDesiree LOIKAS (Vasteras, Sweden)
08:30P3583Comparison of stroke- and bleed-related healthcare resource utilization (HCRU) among patients with non-valvular atrial fibrillation (NVAF), newly treated with oral anti-coagulants (OACs)Jessica FRANCHINO-ELDER (Ridgefield, United States of America)
08:30P3585Real-world single tertiary-care multidisciplinary experience with dabigatran, apixaban, rivaroxaban and warfarin in patients with renal failure and concomitant NVAF.Francesco MELILLO (Milano, Italy)
08:30P3586Efficacy and safety of edoxaban vs. warfarin in patients with atrial fibrillation and hepatic disease: Insights from the ENGAGE AF-TIMI 48 trialArman QAMAR (Boston, United States of America)
08:30P3587Haemostatic and genetic factors, associated with left atrial appendage thrombosis in patients with permanent atrial fibrillationAnatolii RUBANENKO (Samara, Russian Federation)
08:30P3588Effectiveness and safety of apixaban versus warfarin among high-risk subgroups of non-valvular atrial fibrillation patients: a propensity score matched analysisXiaoyan LI (Princeton, United States of America)
08:30P3589Anticoagulation in atrial fibrillation and risk of myocardial infarction: choice of treatment matters.Christina Ji-Young LEE (Kbh V, Denmark)
08:30P3590Rivaroxaban strategies improve the number of days patients remain out of the hospital and event free: A PIONEER substudyC Michael GIBSON (Boston, United States of America)
08:30P3591Impact of changing European guideline oral anticoagulation treatment thresholds on stroke and mortality in patients with atrial fibrillationLaurent FAUCHIER (Tours, France)
08:30P3592Safety analysis of rivaroxaban: a pooled analysis of the global XANTUS programme (real-world, prospective, observational studies for stroke prevention in patients with atrial fibrillation)Paulus KIRCHHOF (Birmingham, United Kingdom)
08:30P3594Stroke risk in patients with asymptomatic atrial fibrillation (AF) detected incidentally in general practice is comparable to symptomatic AF presentation, and AF presenting first to hospitalS Benedict FREEDMAN (Sydney, Australia)
08:30P3595Non-valvular atrial fibrillation, anticoagulants and stroke: the stroke prevention and anticoagulants (SPA) case-control study.Jean-Marc DAVY (Montpellier Cedex 5, France)
08:30P3596Dabigatran, rivaroxaban, and apixaban versus vitamin K antagonists for atrial fibrillation patients at low to intermediate stroke risk: A Danish nationwide cohort study.Alexandar DUKANOVIC (Koebenhavn N, Denmark)
08:30P3597Synergic effects of blood pressure control and quality of anticoagulation control on outcomes in patients with atrial fibrillation: the SPORTIF III and V trialsMarco PROIETTI (Birmingham, United Kingdom)
08:30P3598Anticoagulation control in different ethnic-minority patients receiving vitamin K antagonists for stroke prevention in atrial fibrillation: the west Birmingham AF ProjectHanis ZULKIFLY (Birmingham, United Kingdom)
08:30P3599Antithrombotic treatment for incident atrial fibrillation in patients with permanent pacemakers, is it necessary?Nils EDVARDSSON (Pixbo, Sweden)
08:30P3600Characteristics of 15mg od rivaroxaban patients from the RELOAD studyHendrik BONNEMEIER (Kiel, Germany)
08:30P3601Periprocedural heparin bridging in patients receiving oral anticoagulation: a systematic review and meta-analysisZhi Jian WANG (Beijing, China People's Republic of)
08:30P3602Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): a cluster randomized trial in the primary care settingLars KARLSSON (Linkoping, Sweden)
08:30P3603Effectiveness and safety of standard and lower dose apixaban compared to warfarin in non-valvular atrial fibrillation patients: a propensity score matched analysisXiaoyan LI (Princeton, United States of America)
08:30P3604High cerebrovascular thromboembolic rate after unsuccessful catheter ablation for atrial fibrillationZsuzsanna KIS (Rotterdam, Netherlands)
08:30P3605The usefulness of the TIMI-AF score in the prediction of ischemic stroke and bleeding for Asian patients with atrial fibrillation Tze-Fan CHAO (Taipei, Taiwan ROC)
08:30P3606Clinical outcome of low-dose regimen of dabigatran, apixaban, rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation: a single tertiary care multidisciplinary experience.Francesco MELILLO (Milano, Italy)
08:30P3607Geographical variation in use of oral anticoagulation in patients with atrial fibrillation in Denmark: A nationwide cohort studyAmanda Marie Somer CHRISTESEN (Aarhus C, Denmark)
08:30P3608Dynamic CHA2DS2-VASc score and risk of ischemic stroke in patients with atrial fibrillationTze-Fan CHAO (Taipei, Taiwan ROC)
08:30P3609Which definition of hypertension best defines thromboembolic risk in patients with atrial fibrillation? Data from the GARFIELD-AF registryJohn CAMM (London, United Kingdom)
08:30P3610Predictors of warfarin discontinuation or switching among non-valvular atrial fibrillation patientsXuemei LUO (Groton, United States of America)
08:30P3611Use of ESC guidelines to influence safe prescribing of oral anticoagulants in AF in relation to renal functionDavid ROBERTS (Stockport, United Kingdom)
08:30P3612Antithrombotic use amongst patients at low stroke risk as defined by the CHA2DS2-VASc score: Insight from the prospective SPRINT-AF registryMilan GUPTA (Brampton, Canada)
08:30P3613Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarinDragos VINEREANU (Bucharest, Romania)
08:30P3614Atrial arrhythmias are not associated with stroke in adults with congenital heart disease under current anticoagulation treatmentHayang YANG (Amsterdam, Netherlands)
08:30P3615Inappropriate doses of non-vitamin K oral anticoagulants in clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA RegistryMartin RUIZ ORTIZ (Cordoba, Spain)
08:30P3616optimal INR level to prevent stroke and bleeding in patients with rheumatic mitral stenosis and atrial fibrillation.Rawiwan KAEWKANLAYA (Bangkok, Thailand)
08:30P3617Improving the uptake of anticoagulation for prevention of atrial fibrillation related strokeHelen WILLIAMS (Beckenham, United Kingdom)
08:30P3618Medication burden and perception of anticoagulation treatments in atrial fibrillation patients: results from an international surveyDeirdre LANE (Birmingham, United Kingdom)
08:30P3619Comparative patterns of use of non-vitamin K antagonist oral anticoagulants and risk of haemorrhage in real life. The Stroke Prevention and Anticoagulants (SPA) studyJean-Marc DAVY (Montpellier Cedex 5, France)
08:30P3620The extrinsic and intrinsic pathways of coagulation are considerably activated in patients with paroxysmal atrial fibrillation.Mariya NEGREVA (Varna, Bulgaria)
08:30P3621Incidence of ischemic stroke in a pacemaker populationEmma SANDGREN (Varberg, Sweden)
08:30P3622Timing of trial stoppage for non-inferiority trials and interpretation: lessons from ROCKET AFManesh PATEL (Durham, United States of America)
08:30P3625Monocyte counts predict major bleeding events in patients with atrial fibrillationFarhan SHAHID (Birmingham, United Kingdom)
08:30P3626Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trialJulia AULIN (Uppsala, Sweden)
08:30P3627Relationship between an extent of electroanatomical substrate, serum pro-fibrotic biomarkers and histopathological data in patients with atrial fibrillation and heart failure.Victoria ORSHANSKAYA (Saint Petersburg, Russian Federation)
08:30P3628Age and extent of coronary artery disease are associated with complexity of induced atrial fibrillation Elton DUDINK (Maastricht, Netherlands)
08:30P3629Rotational and Focal AF Sources Localize to Low Voltage Areas Displaying Slow Conduction in Sinus RhythmAmir Sherwan JADIDI (Bad Krozingen, Germany)
08:30P3630Association of complex fractionated electrograms with atrial myocardial thickness and fibrosis: Insights from pathologic analyses of canine heartsSeil OH (Seoul, Korea Republic of)
08:30P3631Determinants of antithrombotic treatment of patients with AF: baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with AF (IMPACT-AF)Dragos VINEREANU (Bucharest, Romania)
08:30P3632Comparison of intravenous vernakalant and electrical cardioversion in recent-onset atrial fibrillation: Effect on time to restore sinus rhythm and length of hospital stayAntti Eetu HEIKKOLA (Kys, Finland)
08:30P3633Incidence of left atrial thrombus prior to direct current cardioversion in patients anticoagulated for 3 weeks or more with warfarin or novel oral anticoagulation.Alexander DASHWOOD (Brisbane, Australia)